Please assess the completion status of the following clinical trial:

Trial Title: Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 20.0

Eligibility Criteria:
Inclusion Criteria:~• Male or female participants between the ages of 18 and 55 years, inclusive, 65 and 85 years, inclusive, or ≥12 years, inclusive, at randomization (dependent upon study phase). For the boostability and protection-against-VOCs subset: Existing participants enrolled to receive a third dose of BNT162b2 at 30 µg or BNT162b2SA; male or female participants between the ages of 18 and 55 years, inclusive, at rerandomization.~Newly enrolled participants enrolled to receive 2 doses of BNT162b2SA; male or female participants between the ages of 18 and 55 years, inclusive, at enrollment.~Existing participants enrolled to receive a third dose of BNT162b2 at 5 or 10 µg; male or female participants ≥18 years at rerandomization.~Note that participants \<18 years of age cannot be enrolled in the EU.~* Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures.~* Healthy participants who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study.~* Participants who, in the judgment of the investigator, are at risk for acquiring COVID-19.~* Boostability and protection-against-VOCs existing participant subset only: Participants who provided a serum sample at Visit 3, with Visit 3 occurring within the protocol-specified window.~* Capable of giving personal signed informed consent~Exclusion Criteria:~* Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.~* Phases 1 and 2 only: Known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV).~* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s).~* Receipt of medications intended to prevent COVID 19.~* Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID 19~* Phase 1 only: Individuals at high risk for severe COVID-19, including those with any of the following risk factors:~  * Hypertension~ * Diabetes mellitus~ * Chronic pulmonary disease~ * Asthma~ * Current vaping or smoking~ * History of chronic smoking within the prior year~ * BMI \>30 kg/m2~ * Anticipating the need for immunosuppressive treatment within the next 6 months~* Phase 1 only: Individuals currently working in occupations with high risk of exposure to SARS-CoV-2 (eg, healthcare worker, emergency response personnel).~* Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.~* Phase 1 only: Individuals with a history of autoimmune disease or an active autoimmune disease requiring therapeutic intervention.~* Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.~* Women who are pregnant or breastfeeding.~* Previous vaccination with any coronavirus vaccine.~* Individuals who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study.~* Phase 1 only: Regular receipt of inhaled/nebulized corticosteroids.~* Receipt of blood/plasma products or immunoglobulin, from 60 days before study intervention administration or planned receipt throughout the study.~* Participation in other studies involving study intervention within 28 days prior to study entry through and including 6 months after the last dose of study intervention, with the exception of non-Pfizer interventional studies for prevention of COVID 19, which are prohibited throughout study participation.~* Previous participation in other studies involving study intervention containing lipid nanoparticles.~* Phase 1 only: Positive serological test for SARS-CoV-2 IgM and/or IgG antibodies at the screening visit.~* Phase 1 only: Any screening hematology and/or blood chemistry laboratory value that meets the definition of a ≥ Grade 1 abnormality.~* Phase 1 only: Positive test for HIV, hepatitis B surface antigen (HBsAg), hepatitis B core antibodies (HBc Abs), or hepatitis C virus antibodies (HCV Abs) at the screening visit.~* Phase 1 only: SARS-CoV-2 NAAT-positive nasal swab within 24 hours before receipt of study intervention.~* Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 10 µg dose, 18-55 years of age (2 doses) (Type: EXPERIMENTAL): None
- 20 µg dose, 18-55 years of age (2 doses) (Type: EXPERIMENTAL): None
- 30 µg dose, 18-55 years of age (2 doses) (Type: EXPERIMENTAL): None
- 10 µg dose, 65-85 years of age (2 doses) (Type: EXPERIMENTAL): None
- 20 µg dose, 65-85 years of age (2 doses) (Type: EXPERIMENTAL): None
- 30 µg dose, 65-85 years of age (2 doses) (Type: EXPERIMENTAL): None
- 30 µg dose, ≥12 years of age (2 doses) (Type: EXPERIMENTAL): None
- Placebo, 18-55 years of age (Type: PLACEBO_COMPARATOR): None
- Placebo, 65-85 years of age (Type: PLACEBO_COMPARATOR): None
- Placebo, ≥12 years of age (Type: PLACEBO_COMPARATOR): None
- 100 µg dose, 18-55 years of age (2 doses) (Type: EXPERIMENTAL): None
- Vaccination of Placebo recipients with BNT162b2 - Stage 1 (Type: OTHER): Participants ≥16 years of age who originally received placebo and are eligible for COVID-19 vaccination following any local or national recommendations will be offered the opportunity to receive BNT162b2 as part of the study.
- Vaccination of placebo recipients with BNT162b2 - Stage 2 (Type: OTHER): Participants ≥16 years of age who originally received placebo will be offered the opportunity to receive BNT162b2 at defined points as part of the study.
- Booster vaccination of Phase 1 participants with BNT162b2 at a dose of 30 µg (Type: EXPERIMENTAL): None
- Booster vaccination of Phase 3 participants with BNT162b2 at a dose of 30 µg (Type: EXPERIMENTAL): None
- Booster vaccination of Phase 3 participants with BNT162b2SA at a dose of 30 µg (Type: EXPERIMENTAL): None
- Vaccination of BNT162b2-naive participants with BNT162b2SA at a dose of 30 µg (Type: EXPERIMENTAL): None
- Booster and further vaccination of Phase 3 participants with BNT162b2SA at a dose of 30 µg (Type: EXPERIMENTAL): None
- Booster vaccination of Phase 3 participants with BNT162b2 at a dose of 5 µg (Type: EXPERIMENTAL): None
- Booster vaccination of Phase 3 participants with BNT162b2 at a dose of 10 µg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete